Compare ELVR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | INBX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | Australia | United States |
| Employees | 230 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 999.7M |
| IPO Year | N/A | 2024 |
| Metric | ELVR | INBX |
|---|---|---|
| Price | $98.74 | $133.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 74.9K | ★ 486.3K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $90.73 | N/A |
| Revenue Next Year | $42.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $15.55 | $12.80 |
| 52 Week High | $99.98 | $155.29 |
| Indicator | ELVR | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 71.83 | 66.58 |
| Support Level | $49.59 | $69.30 |
| Resistance Level | N/A | $155.29 |
| Average True Range (ATR) | 3.50 | 13.75 |
| MACD | 0.52 | 0.62 |
| Stochastic Oscillator | 93.35 | 69.23 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.